Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Clinical trial NCT04653246 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04653246
Sponsor: Jacob Laubach, MD
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Newly Diagnosed Multiple Myeloma (NDMM)Autologous Stem Cell Transplant

Start date: 2021-07-13
Primary completion: 2025-12-15
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.